Literature DB >> 12566185

Effect of treatment for Chlamydia trachomatis during pregnancy.

S Rastogi1, B Das, S Salhan, A Mittal.   

Abstract

OBJECTIVES: To screen and treat chlamydial infection in pregnant women in order to assess the effects of therapeutic intervention on the outcome of Chlamydia trachomatis-infected pregnancy.
METHODS: Enrolled in the study were 350 women in the first to third trimesters of pregnancy. Endocervical swabs were collected for C. trachomatis diagnosis by DFA and PCR. A few STD infections, viz.: Neisseria gonorrhoeae, Candida spp., bacterial vaginosis, Trichomonas vaginalis and Treponema pallidum were ruled out. After excluding 22 patients infected with other sexually transmitted infections, a cohort of 328 pregnant women comprised the study population. Anti-chlamydial treatment (viz.: oral therapy with erythromycin stearate, 500 mg 4 times daily for 7 days) was given to 17 women (group I) and their partners. Fifteen patients of group I were retested by DFA and PCR assay for C. trachomatis infection 2 weeks following therapy. Other Chlamydia-positive patients (n=42) who were lost to follow-up were classified as untreated positive cases (group II) while group III included C. trachomatis negative cases (n=269). Data on obstetric outcome were recorded in a total of 164 cases. Statistical comparison of the data were done using the chi(2)-test and means were compared using Student's t-test.
RESULTS: Among the 350 pregnant women enrolled initially for the study, C. trachomatis positivity was found to be 18.8% (n=66) in the endocervix by DFA and PCR assay. Co-infection with Candida spp., bacterial vaginosis, T. vaginalis and T. pallidum was 2.0%, 1.7%, 1.7% and 0.5%, respectively. None of the pregnant women was infected with N. gonorrhoeae. Pregnant women at an increased risk of chlamydial infection included those who had multiple births and were in second trimester of pregnancy. Fifteen patients of group I became Chlamydia-negative following treatment. Data on obstetric outcome were recorded in 11, 26 and 127 patients of groups I, II and III, respectively. The mean duration of gestation for premature deliveries was found to be significantly higher in group I in comparison with group II [35.5 vs. 33.1 weeks (P<0.05)], thereby showing an improved effect of treatment on pregnancy outcome. The mean of low birth weight births was higher in group I compared with group II (2200.0 vs. 2113.3 g), however, this was statistically non-significant. Stillbirths were significantly higher among group II in comparison with group III [11.5% vs. 4.7% (chi(2)=1.79; P<0.5)]. No stillbirths were recorded in patients who had taken anti-chlamydial treatment.
CONCLUSIONS: Our findings suggest that routine screening and treatment of C. trachomatis infection in pregnant women, especially those in high risk groups, should be mandatory to reduce the adverse effects on obstetric outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566185     DOI: 10.1016/s0020-7292(02)00371-5

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  14 in total

Review 1.  Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries.

Authors:  S Mullick; D Watson-Jones; M Beksinska; D Mabey
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

Review 2.  Prevalence of Curable Sexually Transmitted Infections in Pregnant Women in Low- and Middle-Income Countries From 2010 to 2015: A Systematic Review.

Authors:  D L Joseph Davey; H I Shull; J D Billings; D Wang; K Adachi; J D Klausner
Journal:  Sex Transm Dis       Date:  2016-07       Impact factor: 2.830

3.  Use of pooled urine samples and automated DNA isolation to achieve improved sensitivity and cost-effectiveness of large-scale testing for Chlamydia trachomatis in pregnant women.

Authors:  G I J G Rours; R P Verkooyen; H F M Willemse; E A E van der Zwaan; A van Belkum; R de Groot; H A Verbrugh; J M Ossewaarde
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Prevalence and risk factors of chlamydia and gonorrhea among rural Nepali women.

Authors:  P Christian; S K Khatry; S C LeClerq; A A Roess; L Wu; J D Yuenger; J M Zenilman
Journal:  Sex Transm Infect       Date:  2005-06       Impact factor: 3.519

5.  Sexually transmitted infection screening to prevent adverse birth and newborn outcomes: study protocol for a randomized-controlled hybrid-effectiveness trial.

Authors:  Andrew Medina-Marino; Susan Cleary; Christina A Muzny; Christopher Taylor; Ashutosh Tamhane; Phuti Ngwepe; Charl Bezuidenhout; Shelley N Facente; Koleka Mlisana; Remco P H Peters; Jeffrey D Klausner
Journal:  Trials       Date:  2022-05-24       Impact factor: 2.728

6.  Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women.

Authors:  G I J G Rours; Tamar Anne Smith-Norowitz; Jared Ditkowsky; Margaret R Hammerschlag; R P Verkooyen; R de Groot; H A Verbrugh; M J Postma
Journal:  Pathog Glob Health       Date:  2016 Oct - Dec       Impact factor: 2.894

7.  Chlamydia trachomatis and Adverse Pregnancy Outcomes: Meta-analysis of Patients With and Without Infection.

Authors:  Courtney Olson-Chen; Kripa Balaram; David N Hackney
Journal:  Matern Child Health J       Date:  2018-06

8.  Chlamydia trachomatis infection in HIV-infected women: need for screening by a sensitive and specific test.

Authors:  Sonali Bhattar; Preena Bhalla; Sanjim Chadha; Reva Tripathi; Ravinder Kaur; Kabir Sardana
Journal:  Infect Dis Obstet Gynecol       Date:  2013-12-05

Review 9.  Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy.

Authors:  R Matthew Chico; Rudiger Pittrof; Brian Greenwood; Daniel Chandramohan
Journal:  Malar J       Date:  2008-12-16       Impact factor: 2.979

10.  Low prevalence of Chlamydia trachomatis infection in non-urban pregnant women in Vellore, S. India.

Authors:  Navjyot K Vidwan; Annie Regi; Mark Steinhoff; Jill S Huppert; Mary Allen Staat; Caitlin Dodd; Rida Nongrum; Shalini Anandan; Valsan Verghese
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.